Biotechnology has all the time been a dynamic area, however the world of finance that gives the gas for the fireplace is simply as vibrant. Attempting to foretell the place the marketplace for biotech funding is heading is all the time dangerous however for consultants like Baker McKenzie’s Roel Meers, understanding the place the market is shifting is the place he eats.
I spoke to Roel this week to unpack simply the place biotech funding stands in Q2 2025, to get a really feel for the types of M&As, IPOs, and licensing offers we needs to be in search of within the second half of the yr. We additionally speak about some different financing choices for innovators and early-stage corporations.
01:09 Introducing Roel Meers
02:18 Company finance and the life sciences
04:53 Brussels, Europe, and past: Baker McKenzie’s international footprint
06:21 Navigating life science rules and regulators
10:33 De-risking biotech investments in unsure occasions
11:57 How buyers are minimizing danger in 2025
13:35 Funding developments for biotechs in rising hubs, together with Benelux
15:58 The deal varieties that can dominate 2025
17:35 The therapeutic areas the place offers are being completed
19:16 Developments in biotech in Europe, in North America, and within the Asia-Pacific
20:36 Macroeconomics and biotechnology finance
22:54 De-risking offers by reducing upfronts, rising milestones
26:38 What to contemplate when selecting different financing choices
30:35 When ought to biotechs herald exterior finance consultants
33:47 Trying past 2025 – what’s coming, and why
36:38 How European biotechs can place themselves for funding success
Desirous about being a sponsor of an episode of our podcast? Uncover how one can become involved right here!
Keep up to date by subscribing to our publication
To dive deeper into the subject:
Company finance and the life sciences
Brussels, Europe, and past: Baker Mackenzie’s international footprint
Navigating life science rules and regulators
De-risking biotech investments in unsure occasions
How buyers are minimizing danger in 2025
Funding developments for biotechs in rising hubs, together with Benelux
The deal varieties that can dominate 2025
The therapeutic areas the place offers are being completed
Developments in biotech in Europe, in North America, and within the Asia-Pacific
Macroeconomics and biotechnology finance
De-risking offers by reducing upfronts, rising milestones
What to contemplate when selecting different financing choices
When ought to biotechs herald exterior finance consultants
Trying past 2025 – what’s coming, and why
How European biotechs can place themselves for funding success
